India Lopinavir & Ritonavir Market to Grow at an Impressive Rate through 2025
Increasing number
of COVID-19 cases across the country to drive
the growth of India lopinavir & ritonavir market
According
to TechSci Research report, “India Lopinavir & Ritonavir Market By Dosage Form (Tablet,
Capsule, Oral Solution), By Dosage (Lopinavir 200mg/ Ritonavir 50mg
Co-formulated Tablet, Lopinavir 100mg/ Ritonavir-25mg Co-formulated Capsule,
Lopinavir 400mg/ Ritonavir 100mg/ 10ml Oral Solution), By Application (HIV,
COVID-19, Hepatitis C, Others), By Distribution Channel (Hospitals &
Clinics, Drug Stores/Pharmacies, Online, Others), By End User (Adults v/s
Children (14days of age & above)), By Region, Forecast & Opportunities,
2025”, the India lopinavir &
ritonavir market is expected to grow at an impressive rate during the forecast
period on account of the growing use of the drug combination in treating
various diseases such as HIV, COVID-19, Hepatitis C, among others.
Additionally, growing use of this combination in treatment of COVID-19, which
at present, has no approved drug or treatment, is expected to positively
influence the market growth in the country. Furthermore, the ICMR has received
approval from the Drug Controller General of India to allow the use of this
combination for treatment of novel coronavirus disease. This is expected to
create lucrative opportunities for the market growth. However, this is an
antiretroviral combination which is approved for the treatment of HIV and has
no approval or clinical evidence for treating COVID-19 disease. It is just
being used since no harmful effects have been observed. Additionally,
associated side effects such as diarrhea, nausea, abdominal pain, vomiting,
headache, among others, might hamper the growth of market. Besides, this
combination is quite expensive, and availability of other drugs and generics might
hinder the market growth over next few years. Furthermore, this combination
should be avoided or very cautiously used with heart patients especially those
suffering from ischemic heart disease or cardiomyopathies. This in turn might negatively
impact the market growth through 2025.
Browse XX market data
Tables and XX Figures spread through XXX Pages and an in-depth TOC on" India Lopinavir
& Ritonavir Market"
https://www.techsciresearch.com/report/india-lopinavir-ritonavir-market/4718.html
The India lopinavir & ritonavir market is segmented based on dosage
form, dosage, application, distribution channel, end user company and region.
Based on dosage form, the market can be categorized into tablet, capsule and
oral solution. The tablets segment is expected to dominate the market since
they are inexpensive, safe and effective in delivering oral medication. On the
other hand, the capsules segment is expected to hold a significant market share
on account of their fast action attribute. They breakdown quickly as compared
to the tablets. Additionally, they have higher bioavailability as a result of
which, more drug is likely to enter the bloodstream. Also, they are tasteless
hence do not leave any unpleasant taste or odor. Based on application, the
market can be fragmented into HIV, COVID-19, Hepatitis C and others. The HIV
segment is expected to dominate the market since this combination of drugs is
primarily used for the treatment of HIV and have the approval for that from the
FDA. On the contrary, COVID-19 segment is expected to register significant
growth on account of the increasing use of this combination of drugs for
treating COVID-19 disease that recently grasped the whole country.
AbbVie India, Hetero Drugs Ltd., Aurobindo Pharmaceuticals Limited,
Cipla, Mylan India, Lupin Ltd., Macleods Pharmaceuticals Limited, Discovery
Laboratories Pvt. Ltd., SMS Pharmaceuticals, PCD Pharmaceuticals, Aspire
Lifesciences Pvt. Ltd., Rewine Pharmaceutical, Wellona Pharmaceutical,
Acebright India Pvt. Ltd., Dr. Reddy’s Laboratories and others are some of the
leading players operating in India lopinavir & ritonavir market. The companies operating in the market are using organic
strategies such as product launches, mergers and collaborations to boost their
share.
Download Sample Report @ https://www.techsciresearch.com/sample-report.aspx?cid=4718
Customers can also request for 10% free customization on
this report.
“India lopinavir & ritonavir market
is expected to witness significant growth during the forecast period on account
of the increase in the COVID-19 cases increasing in the country, which at
present has no available treatment. Additionally, the Indian experts say that
they will minimum take 1.5 years to develop a potential vaccine against this
disease. Looking at the current scenario, the department of pharmaceuticals
held a meeting with the major players operating in the Indian market and asked
them to ramp up the production lopinavir & ritonavir and keep the stocks
ready for emergency situations. This is further expected to create lucrative
opportunities for the market growth over the next few years.” said Mr. Karan Chechi, Research Director with
TechSci Research, a research based India management consulting firm.
“India
Lopinavir & Ritonavir Market By Dosage Form (Tablet, Capsule, Oral
Solution), By Dosage (Lopinavir 200mg/ Ritonavir 50mg Co-formulated Tablet,
Lopinavir 100mg/ Ritonavir-25mg Co-formulated Capsule, Lopinavir 400mg/ Ritonavir
100mg/ 10ml Oral Solution), By Application (HIV, COVID-19, Hepatitis C,
Others), By Distribution Channel (Hospitals & Clinics, Drug
Stores/Pharmacies, Online, Others), By End User (Adults v/s Children (14days of
age & above)), By Region, Forecast & Opportunities, 2025”, has evaluated the future growth potential of India lopinavir
& ritonavir market and provides statistics & information on market
size, structure and future market growth. The report intends to provide
cutting-edge market intelligence and help decision makers take sound investment
decisions. Besides, the report also identifies and analyzes the emerging trends
along with essential drivers, challenges and opportunities in India lopinavir
& ritonavir market.
Contact
Mr. Ken Mathews
708 Third Avenue,
Manhattan, NY,
New York – 10017
Tel: +1-646-360-1656
Email: [email protected]